Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma
Status:
Withdrawn
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
To investigate the ability of divalproex sodium, a histone deacetylase inhibitor, to improve
the digital manifestations of scleroderma including digital edema, calcinosis cutis, digital
ulcers, and joint contractures.